Clinical Trial Detail

NCT ID NCT03911973
Title Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Kari Wisinski
Indications

triple-receptor negative breast cancer

Her2-receptor negative breast cancer

Therapies

Gedatolisib + Talazoparib

Age Groups: adult senior

Additional content available in CKB BOOST